GLPwatch
Papers (10410)
Page 153 of 174, ranked by citation count.
- Semaglutide on liver fibrosis and heart outcomes in patients at high risk of liver fibrosis: a prespecified analysis of the SELECT randomized trial.
- EBM BLS: Tirzepatide Remains Effective for Obesity Treatment and Diabetes Prevention at 3 Years of Follow-up.
- Acute Mesenteric Ischemia as a Severe Complication Associated With Tirzepatide: A Case Report and Safety Alert.
- Pancreatitis in Patients Receiving Tirzepatide (Mounjaro): A One-Year Audit in a UK District General Hospital.
- The Use of Glucagon-Like Peptide 1 Agonists Among Non-Diabetics: Evidence From Medicare Part D.
- Semaglutide and Cardiovascular Outcomes.
- After the Prescription: The Clinical Support Gap in Telehealth-Based GLP-1 Care.
- [Combination therapy with glucagon-like peptide-1 analogs and insulin: indications and contraindications in coronary artery disease patients].
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity.
- Renoprotective effect of liraglutide on diabetic nephropathy by modulation of Krüppel-like transcription factor 5 expression in rats.
- Cagrilintide-Semaglutide in Adults with Overweight or Obesity. Reply.
- A Comprehensive Review on the Cardioprotective and Nephroprotective Effects of Semaglutide, and Its Therapeutic Efficacy and Mechanisms in Cardiorenal Syndrome.
- The glucagon-like peptide-1 receptor agonist, Ex4, reduces intromission in sexually experienced male mice.
- PCSK9 Inhibitors in Diabetes, Tirzepatide's Cardiorenal Effects, Shingles Vaccine, and More From ACC.
- Non-Arteritic Ischaemic Optic Neuropathy Associated with Semaglutide Use.
- Psoriasis flare following tirzepatide initiation in a patient with plaque psoriasis in remission: A case report.
- Rapid remission of Hailey-Hailey disease with tirzepatide therapy: A case report.
- Addressing the obesity challenge in plastic surgery - the role of liraglutide.
- Implications of Glucagon-Like Peptide-1 Receptor Agonists in Otolaryngology - Head and Neck Surgery: A Review.
- GLP-1 receptor agonists in atherosclerotic cardiovascular disease and diabetes mellitus or obesity: investigation of the potential role in a German inpatient dataset.
- Real-world Impact of 3 and 4.5 mg Doses of Dulaglutide on Weight and Hemoglobin A1c in Patients With Type 2 Diabetes Mellitus.
- A multi-organ atlas of microcirculatory signatures for systemic profiling of diabetic and therapeutic states.
- Pharmacologic Treatment of Metabolic Dysfunction-Associated Steatotic Liver Disease in the Context of Type 2 Diabetes.
- Real-world use of semaglutide in patients with type 2 diabetes and end-stage renal disease: a multicenter retrospective cohort study.
- Semaglutide Reduces CV Events in High-Risk Patients with Type 2 Diabetes Mellitus.
- Semaglutide and Effort-Based Decision-Making in Major Depressive Disorder: A Randomized Clinical Trial.
- Therapeutic effect of liraglutide on type 2 diabetic patients with nonalcoholic fatty liver disease.
- A Managed Access Protocol for Liraglutide for Weight Management: A Retrospective, Observational Study in Ireland.
- Exenatide Reduces Graft Injury in a Rat Transplantation Model Using Kidneys Donated after Cardiac Death.
- Development and validation of an LC-MS/MS method for Tirzepatide, a dual GIP/GLP-1 receptor agonist, in rat plasma for application to a pharmacokinetic study.
- Resistant and Refractory Obesity: The Complexity of Anti-Obesity Therapy Failure.
- [Pharmacological and clinical profiles of a human GLP-1 analogue, liraglutide (Victoza(®))].
- Acute gastric dilation associated with the use of semaglutide, a GLP-1 analogue.
- Indirect treatment comparisons: Choosing the right tool for the job.
- Will oral semaglutide be used to reduce cardiovascular risk in subjects with type 2 diabetes instead of subcutaneous semaglutide?
- Antidiabetikum vor neuer Karriere.
- Effect of GLP-1 receptor agonists on idiopathic intracranial hypertension: A systematic review.
- Cardiovascular Effectiveness of Semaglutide Versus Dulaglutide in Type 2 Diabetes.
- Semaglutide ameliorates aortic endothelial cell dysfunction in sarcopenia through the SIRT1/cGAS-STING signaling axis.
- R WE ready for reimbursement? A round-up of developments in real-world evidence relating to health technology assessment: part 25.
- Weight Loss With GLP-1 Agonists in Nondiabetic Adults: Systematic Review and Network Meta-Analysis.
- Safety of Semaglutide After Dialysis Initiation: An Individual-Level Pooled Analysis.
- [Indicators of diabetes mellitus after liraglutide, sitagliptin/metformin, linagliptin, and sitagliptin].
- Antihyperglycemic medications for cardiovascular disease risk reduction.
- Mental health outcomes in obesity interventions with GLP-1 receptor agonists: is it similar to other obesity interventions? A narrative review with systematic evidence synthesis.
- Transdermal "Natural GLP-1" Dietary Supplements Violate Law and Place Patients at Risk.
- Comparative effects of lifestyle modification, metformin and exenatide/glargine combination therapy on daily glycaemic fluctuation in the setting of near-normoglycaemia.
- Design and fabrication of a mesoporous silica scaffold for oral delivery of peptides.
- [Semaglutide 2.4 mg (Wegovy®) for the management of clinical obesity with weight-related complications].
- Predicting Long-Term Weight Loss Using Self-Reported, Digitally Collected, Real-World Data After Initiation of Semaglutide for Overweight or Obesity.
- The evidence for oral semaglutide in type 2 diabetes from a managed care perspective.
- Roflumilast Enhances Liraglutide's Atrial Natriuretic Peptide-Dependent Suppression of Adrenal Aldosterone Secretion.
- Ketoacidosis associated with tirzepatide use in a nonobese individual without diabetes.
- Decoding the hallmarks of GLP-1RA weight-loss super-responders.
- Facial nodules following filler injections after initiating compounded tirzepatide use.
- Benefits and Harms of Pharmacologic Treatments in Adults With Overweight or Obesity: A Living Systematic Review and Network Meta-analysis for the American College of Physicians.
- [Cardiac effects of glucagon-like peptide 1].
- Perceptions and Attitudes Toward Oral Semaglutide Among Japanese Physicians and Individuals with Type 2 Diabetes: A Web-Based Survey.
- Hemoglobin A1c levels in patients with type 2 diabetes mellitus receiving oral semaglutide with versus without proton pump inhibitors: An exploratory study.
- [Among adults with cardiovascular disease and BMI≥27kg/m<sup>2</sup> but no diabetes, does semaglutide lower risk of cardiovascular mortality, myocardial infarction, or stroke when compared with placebo, and is it safe?]